SL
CATX icon

Sentinus LLC’s Perspective Therapeutics CATX Stock Holding History

Sentinus LLC’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$687K Buy
164,821
+107
+0.1% +$452 0.06% 233
2025
Q4 		$453K Buy
164,714
+3
+0% +$9 0.04% 322
2025
Q3 		$565K Buy
+164,711
New +$600K 0.12% 116

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sentinus LLC's CATX Position: Q1 2026 in Review

Sentinus LLC increased its Perspective Therapeutics (CATX) stake by 0.06% in Q1 2026, buying an estimated $452 and bringing the position to 164,821 shares worth $687K. The position accounts for 0.06% of the portfolio, ranked #233.

Sentinus LLC first reported a position in CATX in Q3 2025 and has held it in 3 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Sentinus LLC held 164,821 shares of Perspective Therapeutics worth $687K as of Q1 2026.
  • Sentinus LLC bought 107 Perspective Therapeutics shares in Q1 2026, an estimated $452.
  • Perspective Therapeutics made up 0.06% of Sentinus LLC's portfolio in Q1 2026, its #233 holding.
  • Sentinus LLC first reported a position in Perspective Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Sentinus LLC's 13F filing for Q1 2026, filed 6 May 2026.